Yuk Ting

Madras Institute of Orthopaedics and Traumatology — India

Medicine · Health Sciences

25h-index6.6kcitations166works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(47), Pancreatic and Hepatic Oncology Research(36), Cancer Immunotherapy and Biomarkers(21), Cholangiocarcinoma and Gallbladder Cancer Studies(20), Immune cells in cancer(18)

Publications166 total

Nutrient-stimulated Hormone-based Therapies: A New Frontier in the Prevention and Management of MASH-associated Hepatocellular Carcinoma
Journal of Clinical and Translational Hepatology·2025Open Access
UK Real-World Evidence of Using Durvalumab Plus Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer via an Early Access Scheme
Cancers·2025· 1 citedOpen Access
Addition of a dendritic cell vaccine to conditioning cyclophosphamide and chemoembolisation to prolong progression-free survival in patients with hepatocellular carcinoma: the ImmunoTACE RCT
Efficacy and Mechanism Evaluation·2025Open Access
ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine
Future Oncology·2025Open Access
Addition of Dendritic Cell Vaccination to Conditioning Cyclophosphamide and Chemoembolization in Patients with Hepatocellular Carcinoma: The ImmunoTACE Trial
Clinical Cancer Research·2025· 4 citedOpen Access
IL-17A as a Key Mediator of Pulmonary-Intestinal Immune Interactions in a Mouse Model of Asthma and Colitis
Journal of Inflammation Research·2025· 1 citedOpen Access
Hyperparathyroidism with multiple brown tumors throughout the body: A case report
Asian Journal of Surgery·2025Open Access
WCN25-2545 A QUANTUM LEAP IN RENAL SCIENCE: THE FIRST EVER ABH INCOMPATIBLE RENAL TRANSPLANT IN A RECIPIENT WITH BOMBAY BLOOD PHENOTYPE
Kidney International Reports·2025Open Access
WCN25-1879 LUTETIUM IN THE TREATMENT OF METASTATIC NEUROENDOCRINE TUMOUR IN A PATIENT ON MAINTENANCE HEMODIALYSIS - A CASE REPORT
Kidney International Reports·2025· 1 citedOpen Access
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Journal of Clinical Oncology·2024· 19 citedOpen Access
Supplementary Data from Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2024Open Access
Supplementary Table 3 from Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2024Open Access
Supplementary Table 2 from Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2024Open Access
Data from Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2024Open Access
Supplementary Table 1 from Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2024Open Access
Supplementary Data file 2 from Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
2024Open Access
Data from Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
2024Open Access
Tables from Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
2024Open Access
Supplementary Data file 1 from Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
2024Open Access
Figures from Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
2024Open Access
page 1 of 9Next →

Frequent Co-authors

Daniel H. Palmer(25), Paul J. Ross(17), Juan W. Valle(13), Tim Meyer(13), Jonathan Wadsley(11), Harpreet Wasan(11), Stephen Falk(10), John P. Neoptolemos(8), David Cunningham(8), Roopinder Gillmore(8), Alan Anthoney(7), John Bridgewater(7), Olusola Olusesan Faluyi(6), Suzanne Darby(6), Kinnari Patel(6), Richard Hubner(6), Lucy Wall(5), JEFF EVANS(5), Timothy Iveson(5), Shishir Shetty(5)